



Whereby I certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on November 13, 2006.

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. ARS-125
Serial No. 10/570,121

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ilya Chumakov, Oxana Guerassimenko
Serial No. : 10/570,121
Filed : February 28, 2006
Conf. No. : 7412
For : Novel UBP8rp Polypeptides and Their Use in the Treatment of Psoriasis

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/570,121
Filing Date	February 28, 2006
First Named Inventor	Ilya Chumakov
Art Unit	
Examiner Name	
Attorney Docket Number	ARS-125

Sheet

1

of

5

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1	WO 01/75067 (CD-ROM)	10-11-2001	HYSEQ, INC.	All	
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/570,121
Filing Date	February 28, 2006
First Named Inventor	Ilya Chumakov
Group Art Unit	
Examiner Name	
Attorney Docket Number	ARS-125

Sheet 2 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	ALTSCHUL, S. F. <i>et al.</i> "Basic Local Alignment Search Tool", <i>J. Mol. Biol.</i> , 1990, pp. 403-410, Vol. 215.	
	R2	ASUMALAHTI, K. <i>et al.</i> "Genetic Analysis of PSORS1 Distinguishes Guttate Psoriasis and Palmoplantar Pustulosis", <i>J. Invest. Dermatol.</i> , 2003, pp. 627-632, Vol. 120.	
	R3	BORRESEN, A.-L. <i>et al.</i> "Detection of Base Mutations in Genomic DNA Using Denaturing Gradient Gel Electrophoresis (DGGE) Followed by Transfer and Hybridization With Gene-Specific Probes", <i>Mutation Research</i> , 1988, pp. 77-83, Vol. 202.	
	R4	CATHER, J. C. <i>et al.</i> "Modulating T Cell Responses for the Treatment of Psoriasis: a Focus on Efalizumab", <i>Expert Opin. Biol. Ther.</i> , 2003, pp. 361-370, Vol. 3, No. 2.	
	R5	DEMPSTER, A. P. <i>et al.</i> "Maximum Likelihood from Incomplete Data via the EM Algorithm", <i>JSSRB</i> , 1977, pp. 1-38, Vol. 39.	
	R6	DEVEREUX, J. <i>et al.</i> "A Comprehensive Set of Sequence Analysis Programs for the VAX", <i>Nucleic Acids Research</i> , 1984, pp. 387-395, Vol. 12, No. 1.	
	R7	EDDY, S. R. "Hidden Markov Models", <i>Current Opinion in Structural Biology</i> , 1996, pp. 361-365, Vol. 6.	
	R8	ELBASHIR, S. M. <i>et al.</i> "Duplexes of 21-nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells", <i>Nature</i> , May 24, 2001, pp. 494-498, Vol. 411.	
	R9	ELLINGTON, A. D. <i>et al.</i> "In Vitro Selection of RNA Molecules that Bind Specific Ligands", <i>Nature</i> , August 30, 1990, pp. 818-822, Vol. 346.	
	R10	EXCOFFIER, L. <i>et al.</i> "Maximum-Likelihood Estimation of Molecular Haplotype Frequencies in a Diploid Population", <i>Mol. Biol. Evol.</i> , 1995, pp. 921-927, Vol. 12, No. 5.	
	R11	FARBER, E. M. <i>et al.</i> "Natural History of Psoriasis in 61 Twin Pairs", <i>Arch Dermatol.</i> , February 1974, pp. 207-211, Vol. 109.	
	R12	FIELDS, S. <i>et al.</i> "A Novel Genetic System to Detect Protein-Protein Interactions", <i>Nature</i> , July 20, 1989, pp. 245-246, Vol. 340.	


Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

5

Complete if Known

Application Number	10/570,121
Filing Date	February 28, 2006
First Named Inventor	Ilya Chumakov
Group Art Unit	
Examiner Name	
Attorney Docket Number	ARS-125

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R13	FREDRIKSSON, T. <i>et al.</i> "Severe Psoriasis-Oral Therapy with a New Retinoid", <i>Dermatologica</i> , 1978, pp. 238-244, Vol. 157.	
	R14	FROMONT-RACINE, M. <i>et al.</i> "Toward a Functional Analysis of the Yeast Genome Through Exhaustive Two-Hybrid Screens", <i>Nature Genetics</i> , July 1997, pp. 277-282, Vol. 16.	
	R15	GNESUTTA, N. <i>et al.</i> "Cloning and Characterization of Mouse UBP _y , a Deubiquitinating Enzyme That Interacts with the Ras Guanine Nucleotide Exchange Factor CDC25 ^{Mm} /Ras-GRF1", <i>The Journal of Biological Chemistry</i> , October 19, 2001, pp. 39448-39454, Vol. 276, No. 42.	
	R16	GOTTLIEB, A. B. <i>et al.</i> "The National Psoriasis Foundation Psoriasis Score (NPF-PS) System Versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): A Comparison", <i>J. Drugs Dermatol.</i> , 2003, pp. 260-266, Vol. 3.	
	R17	GRANTHAM, R. "Amino Acid Difference Formula to Help Explain Protein Evolution", <i>Science</i> , September 6, 1974, pp. 862-864, Vol. 185.	
	R18	GROMPE, M. <i>et al.</i> "Scanning Detection of Mutations in Human Ornithine Transcarbamoylase by Chemical Mismatch Cleavage", <i>Proc. Natl. Acad. Sci. USA</i> , August 1989, pp. 5888-5892, Vol. 86.	
	R19	GUILLAUMEUX, T. <i>et al.</i> "The Complete Genomic Sequence of 424,015 bp at the Centromeric End of the HLA Class I Region: Gene Content and Polymorphism", <i>Proc. Natl. Acad. Sci. USA</i> , August 1998, pp. 9494-9499, Vol. 95.	
	R20	KATO, M. <i>et al.</i> "A Deubiquitinating Enzyme UBPY Interacts with the Src Homology 3 Domain of Hrs-binding Protein via a Novel Binding Motif PX(V/I)(D/N)RXKKP", <i>The Journal of Biological Chemistry</i> , December 1, 2000, pp. 37481-37487, Vol. 275, No. 48.	
	R21	KIM, S. <i>et al.</i> "Multiplex Genotyping of the Human β 2-Adrenergic Receptor Gene Using Solid-Phase Capturable Dideoxynucleotides and Mass Spectrometry", <i>Analytical Biochemistry</i> , 2003, pp. 251-258, Vol. 316.	
	R22	LEE, Y.-A. <i>et al.</i> "Genomewide Scan in German Families Reveals Evidence for a Novel Psoriasis-Susceptibility Locus on Chromosome 19p13", <i>Am. J. Hum. Genet.</i> , 2000, pp. 1020-1024, Vol. 67.	
	R23	LESSA, E. P. <i>et al.</i> "Screening Techniques for Detecting Allelic Variation in DNA Sequences", <i>Molecular Ecology</i> , 1993, pp. 119-129, Vol. 2.	
	R24	LIVAK, K. J. <i>et al.</i> "Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 ^{-$\Delta\Delta C_T$} Method", <i>Methods</i> , 2001, pp. 402-408, Vol. 25.	


Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

5

Complete if Known

Application Number	10/570,121
Filing Date	February 28, 2006
First Named Inventor	Ilya Chumakov
Group Art Unit	
Examiner Name	
Attorney Docket Number	ARS-125

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R25	NAIR, R. P. <i>et al.</i> "Evidence for Two Psoriasis Susceptibility Loci (HLA and 17q) and Two Novel Candidate Regions (16q and 20p) by Genome-Wide Scan", <i>Human Molecular Genetics</i> , 1997, pp. 1349-1356, Vol. 6, No. 8.	
	R26	NAVIGLIO, S. <i>et al.</i> "UBPY: A Growth-Regulated Human Ubiquitin Isopeptidase", <i>The EMBO Journal</i> , 1998, pp. 3241-3250, Vol. 17, No. 12.	
	R27	NEWTON, C. R. <i>et al.</i> "Analysis of Any Point Mutation in DNA. The Amplification Refractory Mutation System (ARMS)", 1989, pp. 2503-2516, Vol. 17, No. 7.	
	R28	NIELSEN, H. <i>et al.</i> "Machine Learning Approaches for the Prediction of Signal Peptides and Other Protein Sorting Signals", <i>Protein Engineering</i> , 1999, pp. 3-9, Vol. 12, No. 1.	
	R29	OKA, A. <i>et al.</i> "Association Analysis Using Refined Microsatellite Markers Localizes a Susceptibility Locus for Psoriasis Vulgaris Within a 111 kb Segment Telomeric to the HLA-C gene", <i>Human Molecular Genetics</i> , 1999, pp. 2165-2170, Vol. 8, No. 12.	
	R30	OLDENBURG, K. R. <i>et al.</i> "Peptide Ligands for a Sugar-Binding Protein Isolated From a Random Peptide Library", <i>Proc. Natl. Acad. Sci. USA</i> , June 1992, pp. 5393-5397, Vol. 89.	
	R31	ORITA, M. <i>et al.</i> "Detection of Polymorphisms of Human DNA by Gel Electrophoresis as Single-Strand Conformation Polymorphisms", <i>Proc. Natl. Acad. Sci. USA</i> , April 1989, pp. 2766-2770, Vol. 86.	
	R32	PARMLEY, S. F. <i>et al.</i> "Antibody-Selectable Filamentous fd Phage Vectors: Affinity Purification of Target Genes", <i>Gene</i> , 1988, pp. 305-318, Vol. 73.	
	R33	PEARSON, W. R. "Rapid and Sensitive Sequence Comparison with FASTP and FASTA", <i>Methods in Enzymology</i> , 1993, pp. 63-98, Vol. 183.	
	R34	PEARSON, W. R. <i>et al.</i> "Improved Tools for Biological Sequence Comparison", <i>Proc. Natl. Acad. Sci. USA</i> , April 1988, pp. 2444-2448, Vol. 85.	
	R35	RASMUSSEN, R. K. <i>et al.</i> "Two-Dimensional Electrophoretic Analysis of Human Breast Carcinoma Proteins: Mapping of Proteins that Bind to the SH3 Domain of Mixed Lineage Kinase MLK2", <i>Electrophoresis</i> , 1997, pp. 588-598, Vol. 18.	
	R36	RUANO, G. <i>et al.</i> "Haplotype of Multiple Polymorphisms Resolved by Enzymatic Amplification of Single DNA Molecules", <i>Proc. Natl. Acad. Sci. USA</i> , August 1990, pp. 6296-6300, Vol. 87.	


Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

5

Complete if Known

Application Number	10/570,121
Filing Date	February 28, 2006
First Named Inventor	Ilya Chumakov
Group Art Unit	
Examiner Name	
Attorney Docket Number	ARS-125

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R37	SARKAR, G. <i>et al.</i> "Haplotyping by Double PCR Amplification of Specific Alleles", <i>BioTechniques</i> , 1991, pp. 436-440, Vol. 10, No. 4.	
	R38	SMITH, T. F. <i>et al.</i> "Comparative Biosequence Metrics", <i>J. Mol. Evol.</i> , 1981, pp. 38-46, Vol. 18.	
	R39	TREMBATH, R. C. <i>et al.</i> "Identification of a Major Susceptibility Locus on Chromosome 6p and Evidence for Further Disease Loci Revealed by a Two Stage Genome-Wide Search in Psoriasis", <i>Human Molecular Genetics</i> , 1997, pp. 813-820, Vol. 6, No. 5.	
	R40	VALADON, P. <i>et al.</i> "Enhancement of ELISAs for Screening Peptides in Epitope Phage Display Libraries", <i>Journal of Immunological Methods</i> , 1996, pp. 171-179, Vol. 197.	
	R41	VEAL, C. D. <i>et al.</i> "Identification of a Novel Psoriasis Susceptibility Locus at 1p and Evidence of Epistasis Between <i>PSORS1</i> and Candidate Loci", <i>J. Med. Genet.</i> , 2001, pp. 7-13, Vol. 38.	
	R42	VEAL, C. D. <i>et al.</i> "Family-Based Analysis Using a Dense Single-Nucleotide Polymorphism-Based Map Defines Genetic Variation at <i>PSORS1</i> , the Major Psoriasis-Susceptibility Locus", <i>Am. J. Hum. Genet.</i> 2002, pp. 554-564, Vol. 71.	
	R43	VON HEIJNE, G. "Membrane Protein Structure Prediction Hydrophobicity Analysis and the Positive-Inside Rule", <i>J. Mol. Biol.</i> , 1992, pp. 487-494, Vol. 225.	
	R44	WEN, S.-Y. <i>et al.</i> "Rapid Detection of the Known SNPs of CYP2C9 Using Oligonucleotide Microarray", <i>World J. Gastroenterol.</i> , 2003, pp. 1342-1346, Vol. 9, No. 6.	
	R45	WILKINSON, K. D. "Regulation of Ubiquitin-Dependent Processes by Deubiquitinating Enzymes", <i>FASEB J.</i> , December 1997, pp. 1245-1256, Vol. 11.	
	R46	WILKINSON, K. D. <i>et al.</i> "Metabolism of the Polyubiquitin Degradation Signal: Structure, Mechanism, and Role of Isopeptidase T", <i>Biochemistry</i> , 1995, pp. 14535-14546, Vol. 34.	
	R47	WU, D. Y. <i>et al.</i> "Allele-Specific Enzymatic Amplification of β -Globin Genomic DNA for Diagnosis of Sickle Cell Anemia", <i>Proc. Natl. Acad. Sci. USA</i> , April 1989, pp. 2757-2760, Vol. 86.	
	R48	ZOLLNER, T. M. <i>et al.</i> "Proteasome Inhibition Reduces Superantigen-Mediated T Cell Activation and the Severity of Psoriasis in a SCID-hu Model", <i>The Journal of Clinical Investigation</i> , March 2002, pp. 671-679, Vol. 109, No. 5.	
	R49	Database SNP 'Online!', SNP ID AP000508.1_67838, September 21, 2001, XP 002275856, retrieved from NCBI, Database Accession No. SS4027402.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.